Department of Oncology, Affiliated Hospital of Southwest Medical University, Sichuan Luzhou 646600, China.
Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Sichuan Luzhou 646600, China.
Int J Biol Sci. 2022 Apr 24;18(7):3066-3081. doi: 10.7150/ijbs.71163. eCollection 2022.
During the development of COVID-19 caused by SARS-CoV-2 infection from mild disease to severe disease, it can trigger a series of complications and stimulate a strong cellular and humoral immune response. However, the precise identification of blood immune cell response dynamics and the relevance to disease progression in COVID-19 patients remains unclear. We propose for the first time to use changes in cell numbers to establish new subgroups, which were divided into four groups: first from high to low cell number (H_L_Group), first from low to high (L_H_Group), continuously high (H_Group), and continuously low (L_Group). It was found that in the course of disease development. In the T cell subgroup, the immune response is mainly concentrated in the H_L_Group cell type, and the complications are mainly in the L_H_Group cell type. In the NK cell subgroup, the moderate patients are mainly related to cellular immunity, and the severe patients are mainly caused by the disease, while severe patients are mainly related to complications caused by diseases. Our study provides a dynamic response of immune cells in human blood during SARS-CoV-2 infection and the first subgroup analysis using dynamic changes in cell numbers, providing a new reference for clinical treatment of COVID-19.
在 SARS-CoV-2 感染引起的 COVID-19 从轻症向重症发展过程中,可引发一系列并发症,并刺激强烈的细胞和体液免疫应答。然而,COVID-19 患者血液免疫细胞反应动态变化及其与疾病进展的相关性仍不明确。我们首次提出利用细胞数量的变化来建立新的亚群,分为四组:细胞数量先高后低(H_L_Group)、细胞数量先低后高(L_H_Group)、持续高(H_Group)和持续低(L_Group)。研究发现,在疾病进展过程中,在 T 细胞亚群中,免疫反应主要集中在 H_L_Group 细胞类型,并发症主要集中在 L_H_Group 细胞类型。在 NK 细胞亚群中,中度患者主要与细胞免疫有关,重症患者主要由疾病引起,而重症患者主要与疾病引起的并发症有关。本研究提供了 SARS-CoV-2 感染期间人类血液中免疫细胞的动态反应,并首次利用细胞数量的动态变化进行亚群分析,为 COVID-19 的临床治疗提供了新的参考。